Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals develops novel therapeutics based on RNA interference. Marketed products include ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. The company also develops treatments for various diseases, including transthyretin amyloidosis, complement-mediated diseases, and more. Alnylam has collaborations with Regeneron Pharmaceuticals and Roche to develop RNAi therapeutics. It also has license and collaboration agreements with Novartis AG, Vir Biotechnology, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Overview
Strengths
- Consistent growth: revenue has compounded at 60.2% a year over 6 years, rising every year.
- ROIC of 25.3% beats 80% of its 128 Biotechnology peers (median 0.0%).
- Paying down debt: long-term debt fell by 3.9 percentage points of total assets last year.
Weaknesses
- Unreliable cash generation: free cash flow was negative in 5 of the last 7 years.
- Heavy interest burden: interest expense absorbs 44% of operating profit.
- Our discounted cash flow target price (54.21 USD) is 65% below the current price.
- Valued at a premium to its Biotechnology peers: P/E 65.8x vs. a median of 19.2x, P/FCF 44.4x vs. a median of 18.8x and EV/EBITDA 30.0x vs. a median of 15.0x.
- Unstable profitability: operating margin ranged from -427% to 14% over the last 7 years, with operating losses in 6 of them.
- Margin pressure: gross margin fell 4.0 percentage points last year, pointing to pricing pressure or rising costs.
Key Financial Data